Online inquiry

IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11682MR)

This product GTTS-WQ11682MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets influenza B virus hemagglutinin gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056660.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 956538
UniProt ID P03460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11682MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10614MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ5651MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ12083MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ12358MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ13324MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ7773MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ6390MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ11908MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW